Dermatology Research and Practice

Tracking and Treating Malignant Melanoma Metastases


Publishing date
15 Nov 2011
Status
Published
Submission deadline
15 May 2011

1Department of Dermatopathology, CHU Sart Tilman, 4000 Liège, Belgium

2Department of Dermatology, University Hospital, University of Franche-Comté, Inserm U645, IFR 133, 25030 Besançon, France

3Department of Dermatopathology, CHU Sart Tilman, University of Liège, 4000 Liège, Belgium


Tracking and Treating Malignant Melanoma Metastases

Description

The metastatic spread of malignant melanoma (MM) cells is a leading cause of death from skin cancers worldwide. Beyond diagnosing and treating early primary MM, searching for and eradicating MM metastases represent the main endeavour clinicians make for these patients. Potential topics include, but are not limited to:

  • Clinical and biological clues for MM progression
  • Staging of metastatic MM
  • Diagnostic functional imaging
  • Immunohistochemistry and molecular studies
  • MM stem cells and MM circulating cells
  • Mechanisms of MM metastasis
  • The 4 routes of MM metastases (intravascular, intramural, perivascular, and interstitial)
  • MM metastases and the tumoral growth fraction
  • Prognosis of metastatic MM
  • Therapy of metastatic MM including anti-MM vaccines

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/drp/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable:


Articles

  • Special Issue
  • - Volume 2012
  • - Article ID 173491
  • - Editorial

Tracking and Treating Malignant Melanoma Metastases

Gérald E. Piérard | Philippe Humbert | Pascale Quatresooz
  • Special Issue
  • - Volume 2012
  • - Article ID 260643
  • - Review Article

A Synopsis of Serum Biomarkers in Cutaneous Melanoma Patients

Pierre Vereecken | Frank Cornelis | ... | Jean-François Baurain
  • Special Issue
  • - Volume 2012
  • - Article ID 259170
  • - Review Article

Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the Treatment of Metastatic Malignant Melanoma

Felipe Ades | Otto Metzger-Filho
  • Special Issue
  • - Volume 2012
  • - Article ID 362784
  • - Review Article

Thigmotropism of Malignant Melanoma Cells

Pascale Quatresooz | Claudine Piérard-Franchimont | ... | Gérald E. Piérard
  • Special Issue
  • - Volume 2012
  • - Article ID 461278
  • - Review Article

Smouldering Malignant Melanoma and Metastatic Dormancy: An Update and Review

Gérald E. Piérard | Claudine Piérard-Franchimont | ... | Pascale Quatresooz
  • Special Issue
  • - Volume 2012
  • - Article ID 156068
  • - Review Article

Biomarkers as Key Contributors in Treating Malignant Melanoma Metastases

Camila Ferreira de Souza | Alice Santana Morais | Miriam Galvonas Jasiulionis
  • Special Issue
  • - Volume 2012
  • - Article ID 182157
  • - Review Article

Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?

Gérald E. Piérard | François Aubin | Philippe Humbert
  • Special Issue
  • - Volume 2012
  • - Article ID 684032
  • - Review Article

Molecular Dermatopathology in Malignant Melanoma

Marie-Annick Reginster | Claudine Pierard-Franchimont | ... | Pascale Quatresooz
  • Special Issue
  • - Volume 2012
  • - Article ID 354191
  • - Review Article

RAS/RAF/MEK/ERK and PI3K/PTEN/AKT Signaling in Malignant Melanoma Progression and Therapy

Ichiro Yajima | Mayuko Y. Kumasaka | ... | Masashi Kato
  • Special Issue
  • - Volume 2012
  • - Article ID 941921
  • - Review Article

Review of Diagnostic Imaging Modalities for the Surveillance of Melanoma Patients

Yan Xing | Kate D. Cromwell | Janice N. Cormier
Dermatology Research and Practice
 Journal metrics
Acceptance rate30%
Submission to final decision42 days
Acceptance to publication34 days
CiteScore1.920
Impact Factor-
 Submit

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.